Aditxt Inc. Announces 1-for-113 Reverse Stock Split to Regain Nasdaq Compliance
TL;DR
Aditxt's reverse stock split could boost share price to meet Nasdaq requirements, potentially attracting new investors and stabilizing the company's market position.
Aditxt will execute a 1-for-113 reverse stock split on November 3, 2025, converting every 113 shares into one share with fractional shares rounded up.
This financial restructuring supports Aditxt's mission to accelerate health innovations that address autoimmune diseases, cancer detection, and women's health challenges globally.
Aditxt's dramatic 1-for-113 reverse split demonstrates how companies use creative financial strategies to maintain their Nasdaq listing while pursuing medical breakthroughs.
Aditxt Inc. (NASDAQ: ADTX) will implement a 1-for-113 reverse stock split of its common stock effective at the opening of trading on November 3, 2025. The company's stock will continue trading under the symbol ADTX following this corporate action. This reverse split means that every 113 shares of issued and outstanding common stock will convert into one share, with fractional shares being rounded up to the nearest whole share.
The decision to proceed with the reverse stock split received stockholder approval on September 23, 2025. The primary objective behind this corporate restructuring is to help Aditxt regain compliance with Nasdaq's minimum bid price requirement. Stock exchanges like Nasdaq maintain specific listing standards that companies must meet to continue trading on their platforms, and the minimum bid price requirement is one of these critical standards designed to ensure market quality and investor protection.
Aditxt operates as a social innovation platform focused on accelerating promising health innovations. The company's ecosystem brings together research institutions, industry partners, and shareholders to collaboratively drive its mission to "Make Promising Innovations Possible Together." The innovation platform serves as the cornerstone of Aditxt's strategy, where multiple disciplines work together to drive disruptive growth and address significant societal challenges in healthcare.
The company's unique operational model emphasizes democratizing innovation, ensuring every stakeholder's voice is heard and valued, and empowering collective progress. Aditxt currently operates four distinct programs targeting major health challenges: autoimmunity, cancer and early disease detection, infectious diseases, and women's health. These focus areas represent some of the most pressing medical needs in contemporary healthcare.
For investors and market participants, reverse stock splits often signal a company's commitment to maintaining its exchange listing and potentially improving its market perception. While the immediate effect increases the stock price mathematically, the long-term success depends on the company's underlying business performance and growth prospects. Investors can access additional information through the company's newsroom at https://ibn.fm/ADTX.
The broader implications of this corporate action extend beyond immediate compliance concerns. Maintaining Nasdaq listing provides Aditxt with continued access to public markets, enhanced visibility among institutional investors, and the credibility that comes with meeting exchange standards. For the biotechnology and healthcare innovation sector, such corporate maneuvers reflect the challenging financial landscape that emerging health technology companies often navigate while developing their platforms and advancing their research programs.
Curated from InvestorBrandNetwork (IBN)